The effect of indomethacin on breathlessness in patients with diffuse parenchymal disease of the lung.
We have shown in a previous study that indomethacin reduced breathlessness in normal subjects during exercise. In a double-blind randomized study we have determined the effects of both acute (50 mg) and chronic (25 mg twice daily for 7 days) oral treatment with indomethacin on breathlessness induced by exercise in patients with diffuse parenchymal disease of the lung. The relationship of breathlessness, as measured on a visual analogue scale, to ventilation was not significantly altered by either acute or chronic treatment with indomethacin compared to placebo. There was no significant change in the distance walked in 6 minutes after any of the treatments. Possible explanations for the differing effects on breathlessness observed in normal subjects and in patients are discussed.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004417:Dyspnea / Q000188:drug therapy* / Q000503:physiopathology; D005080:Exercise Test; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D011658:Pulmonary Fibrosis / Q000503:physiopathology; D011897:Random Allocation; D014797:Vital Capacity
D007213:Indomethacin